Skip to main content

Table 3 Plasma arginine and plasma methylated arginine

From: Oral contraceptives modify DNA methylation and monocyte-derived macrophage function

Arginine type Fs, n = 72 FOCs, n = 67 P value FOCA+, n = 28 FOCA-, n = 39 P value
Arginine (μM) 77.4 ± 15.5 55.7 ± 13.9 < 0.001 55.97 ± 13.86 55.52 ± 14.04 NS
Asymmetric dimethylarginine (μM) 0.5 (0.3 to 0.8) 0.4 (0.3 to 0.7) < 0.001 0.44 ± 0.13 0.41 ± 0.11 NS
Symmetric dimethylarginine (μM) 0.4 (0.2 to 0.7) 0.4 (0.2 to 0.6) NS 0.43 ± 0.09 0.40 ± 0.10 NS
Asymmetric dimethylarginine/asymmetric dimethylarginine 1.2 (0.7 to 1.9) 1.0 (0.6 to 2.4) < 0.001 1.0 (0.6 to 2.0) 0.9 (0.6 to 2.4) NS
Asymmetric dimethylarginine/arginine 0.006 (0.004 to 0.01) 0.007 (0.004 to 0.01) 0.026 0.008 (0.004 to 0.01) 0.007 (0.004 to 0.01) NS
  1. Data are expressed as the mean ± SD or as medians and ranges; n indicates the number of samples used to calculate the statistics.
  2. FOCA+/FOCA- = FOCs further stratified as a function of androgenic (FOCA+) and non-androgenic (FOCA-) properties of progestins; FOCs = women treated with OCs for at least 3 months; Fs = women who had not used OCs for at least 3 months to ensure a sufficient washout period; NS = not significant; OC = oral contraceptive.